MX2017007572A - Composicion acuosa. - Google Patents

Composicion acuosa.

Info

Publication number
MX2017007572A
MX2017007572A MX2017007572A MX2017007572A MX2017007572A MX 2017007572 A MX2017007572 A MX 2017007572A MX 2017007572 A MX2017007572 A MX 2017007572A MX 2017007572 A MX2017007572 A MX 2017007572A MX 2017007572 A MX2017007572 A MX 2017007572A
Authority
MX
Mexico
Prior art keywords
aqueous composition
blocker
solvate
salt
general formula
Prior art date
Application number
MX2017007572A
Other languages
English (en)
Inventor
Oda Hiroshi
Suzuki Yuuki
Sawai Isamu
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of MX2017007572A publication Critical patent/MX2017007572A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Se proporciona una técnica para reducir la decoloración de una composición acuosa que contiene un derivado de isoquinolina halogenado durante la conservación a alta temperatura; una composición acuosa que comprende un compuesto representado por la fórmula (1): (ver Fórmula) en donde x representa un átomo de halógeno, o una sal del mismo, o un solvato del compuesto o la sal del mismo, y un bloqueador ß.
MX2017007572A 2014-12-12 2015-12-11 Composicion acuosa. MX2017007572A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2014251695 2014-12-12
JP2014252192 2014-12-12
JP2014251697 2014-12-12
PCT/JP2015/084804 WO2016093346A1 (ja) 2014-12-12 2015-12-11 水性組成物

Publications (1)

Publication Number Publication Date
MX2017007572A true MX2017007572A (es) 2018-02-09

Family

ID=56107523

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007572A MX2017007572A (es) 2014-12-12 2015-12-11 Composicion acuosa.

Country Status (11)

Country Link
US (1) US20170367977A1 (es)
EP (1) EP3231431A4 (es)
JP (2) JP5951922B1 (es)
KR (1) KR20170093839A (es)
CN (1) CN107106570B (es)
BR (1) BR112017012483A2 (es)
CA (1) CA2970275A1 (es)
MX (1) MX2017007572A (es)
MY (1) MY178370A (es)
SG (1) SG11201704740WA (es)
WO (1) WO2016093346A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3335872A1 (en) * 2016-12-16 2018-06-20 Amcor Flexibles Winterbourne Limited Polymeric films and packages produced therefrom
KR102308566B1 (ko) * 2019-05-28 2021-10-05 서울대학교병원 녹내장 안약의 약물이상반응 진단 키트
JP2020200296A (ja) * 2019-06-13 2020-12-17 久貴 藤本 角膜内皮障害の予防及び／又は治療のための薬剤
US20240082256A1 (en) * 2021-01-21 2024-03-14 Kowa Company, Ltd. Methods of treating fuchs endothelial corneal dystrophy after descemetorhexis
CN114796219A (zh) * 2022-05-18 2022-07-29 沈阳药科大学 一种用于治疗青光眼的复方药物组合物及其用途
KR102552116B1 (ko) 2022-05-26 2023-07-05 이근형 Uv 반사경화를 이용한 uv성형 인쇄시트

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
WO2002022106A2 (en) * 2000-09-14 2002-03-21 Novartis Ag Stable ophthalmic preparation
CA2506464C (en) * 2002-11-18 2012-07-31 Santen Pharmaceutical Co., Ltd. Therapeutic agent for glaucoma comprising rho kinase inhibitor and .beta.-blocker
CA2559630C (en) * 2004-03-16 2012-04-17 Asahi Kasei Pharma Corporation Fasudil-containing preparation and method of improving stability thereof
WO2006115244A1 (ja) * 2005-04-25 2006-11-02 D. Western Therapeutics Institute, Inc. ４－ブロモイソキノリン誘導体及びこれを含有する医薬
KR101333970B1 (ko) * 2005-05-19 2013-11-27 코와 가부시키가이샤 녹내장 예방 또는 치료제
JP2006348028A (ja) * 2005-05-19 2006-12-28 Kowa Co 緑内障予防又は治療剤
JP4800720B2 (ja) * 2005-09-21 2011-10-26 興和株式会社 点眼用組成物
JP2013035802A (ja) * 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
KR101824829B1 (ko) * 2014-01-10 2018-02-01 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물을 포함하는 의약 제제

Also Published As

Publication number Publication date
WO2016093346A1 (ja) 2016-06-16
MY178370A (en) 2020-10-09
JP2016183181A (ja) 2016-10-20
BR112017012483A2 (pt) 2018-01-09
JPWO2016093346A1 (ja) 2017-04-27
CN107106570A (zh) 2017-08-29
CN107106570B (zh) 2021-02-05
KR20170093839A (ko) 2017-08-16
CA2970275A1 (en) 2016-06-16
JP5951922B1 (ja) 2016-07-13
EP3231431A1 (en) 2017-10-18
EP3231431A4 (en) 2018-08-01
SG11201704740WA (en) 2017-07-28
US20170367977A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
MX2017007572A (es) Composicion acuosa.
MX2017007574A (es) Composicion.
MX2017007573A (es) Composicion acuosa novedosa.
PH12018500341A1 (en) Heterocyclic amides as kinase inhibitors
TW201613602A (en) Pharmaceutical product
PH12016500169A1 (en) Polymorph of syk inhibitors
MX2022009299A (es) Derivado de quinolina muy puro y metodo para su produccion.
WO2016011390A8 (en) Irak4 inhibiting agents
MX2015010837A (es) Compuestos de antranilamida, sus mezclas y el uso de los mismos como pesticidas.
ZA202000411B (en) Polymorphs of 5-fluoro-4-imino-3-methyl-1-tosyl-3,4-dihydropyrimidin-2-one
WO2015142903A3 (en) Method of controlling lactate production with piperdine-dione derivatives
MX2016008781A (es) 12-epi-pleuromutilinas.
TW201613603A (en) Pharmaceutical preparation
WO2016159576A3 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
MX2020012771A (es) Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-ami na sustituida.
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
WO2016164295A3 (en) Fused pyridines as adaptor associated kinase 1 (aak1) inhibitors
WO2015191681A3 (en) Substituted pyridinones as mgat2 inhibitors
MX2017010474A (es) Metodo para suprimir el amargor de un derivado de quinoleina.
MX2017003290A (es) Proceso para la preparacion de derivados de trifenilbuteno.
WO2019048923A3 (en) Trans-isomeric heterocyclic compounds and preparation thereof
EP3632917A4 (en) METHOD FOR PRODUCING A HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION WITH THIS COMPOUND, AND HYDRATE OF THIS COMPOUND
AU2018900116A0 (en) Processes for preparing 8-hydroxy quinoline derivatives